Healthcare
•1072 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (1072)
%
| Company | Market Cap | Price |
|---|---|---|
|
Editas Medicine is a biotech company developing in vivo gene-editing therapeutics (gene therapy) using its Cas12a-based platform.
|
$311.41M |
$3.72
-11.85%
|
|
Candel Therapeutics focuses on oncology using viral immunotherapies (CAN-2409, CAN-3110).
|
$310.14M |
$6.19
-6.07%
|
|
Quantum-Si sells diagnostic instruments (Platinum, Proteus platforms) for single-molecule protein sequencing in proteomics.
|
$306.44M |
$1.67
-7.73%
|
|
Core business focus on neuropsychiatric drug development, including navacaprant and NMRA-511 with a CNS/neurodegenerative pipeline.
|
$305.70M |
$1.89
-3.08%
|
|
Alector's ABC Platform is a proprietary platform for delivering diverse therapeutics across the blood-brain barrier, enabling brain-targeted delivery of antibodies and other cargo.
|
$301.98M |
$3.02
-5.48%
|
|
Autoinjector devices are a core planned delivery system for SCPH's at‑home administration of FUROSCIX.
|
$299.33M |
$5.67
|
|
TX45 is a peptide-based therapeutic protein (Fc-relaxin fusion) targeting GPCR RXFP1.
|
$299.13M |
$16.02
-6.10%
|
|
Lead programs target oncology indications (cancer) via galectin-3 inhibition; core business focus.
|
$298.74M |
$4.72
-1.05%
|
|
Aura's lead program bel-sar is a cancer therapy targeting solid tumors, representing its core oncology business.
|
$297.59M |
$5.92
-2.95%
|
|
MPAA distributes/markets diagnostic equipment and test solutions (e.g., JBT-1 bench tester) for engine and EV testing.
|
$296.39M |
$14.89
-2.33%
|
|
CNS/neuropsychiatric drug development focus including RRMS and MDD positions Contineum in the Neuropsychiatric Drug Development theme.
|
$293.64M |
$11.16
-1.63%
|
|
Immutep develops oncology immunotherapies (eftilagimod alfa) for cancer, aligning with Biotech - Oncology.
|
$292.57M |
$2.01
-2.90%
|
|
Direct cell therapy product category; off-the-shelf allogeneic CAR-T (UCART22/UCART20x22).
|
$291.26M |
$4.04
-3.81%
|
|
Senseonics' Eversense CGM system is a diagnostic/monitoring device used to measure glucose levels.
|
$289.52M |
$0.44
-4.70%
|
|
Viaskin Peanut patch is an immunotherapy platform targeting immune modulation in pediatric peanut allergy, aligning with Immunology Therapeutics.
|
$289.50M |
$15.00
-3.29%
|
|
908 Devices directly manufactures handheld chemical analysis instruments (MX908) and FTIR-based devices (ThreatID, XplorIR) for point-of-need diagnostics, i.e., diagnostic equipment.
|
$286.89M |
$8.00
-9.09%
|
|
KYV-101 is an autologous CD19 CAR T-cell therapy, the core product line for Kyverna.
|
$286.54M |
$6.63
-5.69%
|
|
Bright Minds Biosciences develops CNS/psychiatric therapeutics (5-HT receptor agonists) and is advancing BMB-101 in Phase 2, aligning with Neuropsychiatric Drug Development.
|
$282.52M |
$63.29
+2.58%
|
|
Laboratory testing and advisory services offered through LifeMD platform.
|
$280.41M |
$6.17
-5.95%
|
|
Lead oncology candidate MIE-101 immunotherapy platform directly positions the company in Biotech - Oncology.
|
$280.13M |
$0.70
|
|
Larimar focuses on a rare-disease target (Friedreich's ataxia) and develops niche therapeutic solutions, fitting Biotech - Rare Diseases.
|
$279.16M |
$4.36
-3.75%
|
|
Liquid biopsy capabilities (MSK-ACCESS) as part of the diagnostic analytics offerings.
|
$277.71M |
$4.18
-7.32%
|
|
Sanara Surgical includes products and consumables used in surgery (e.g., BIASURGE irrigation), fitting Surgical Equipment.
|
$277.21M |
$31.09
-0.32%
|
|
Core product category is gene therapies using TRACER capsids and payloads (e.g., VY7523, VY1706, APOE, SOD1) enabling IV-delivered CNS gene therapy.
|
$276.68M |
$5.00
-3.29%
|
|
ABEO's lead asset is a gene therapy product targeting recessive dystrophic epidermolysis bullosa (RDEB).
|
$273.18M |
$5.34
-1.11%
|
|
PEDMARK is an FDA-approved oncology therapy addressing cisplatin-induced ototoxicity in pediatric patients, making Biotech - Oncology the core product offering.
|
$272.87M |
$9.82
-0.56%
|
|
Allogene's primary products are off-the-shelf allogeneic CAR T cell therapies (cell therapy).
|
$269.04M |
$1.23
-14.58%
|
|
Atea's lead assets bemnifosbuvir and ruzasvir are oral small-molecule antivirals targeting HCV.
|
$268.72M |
$3.14
+0.32%
|
|
CX-2051 is an EpCAM-directed PROBODY ADC, directly making Antibody-Drug Conjugates.
|
$266.05M |
$3.30
+1.23%
|
|
Ventilator and other home medical equipment rentals/sales align with the Home Health Monitoring Devices category (at-home medical devices).
|
$265.20M |
$6.71
+0.75%
|
|
The company sells proprietary cardiology/interventional devices (MAGiC, MAGiC Sweep, Map-iT, EMAGIN, etc.) directly to hospitals.
|
$264.02M |
$3.07
-9.17%
|
|
Lyell's core direct product is LYL314, a CAR-T cell therapy (cell therapy) targeting cancer, which directly aligns with Biotech - Cell Therapy.
|
$262.11M |
$17.75
+11.99%
|
|
Tablo system includes patient/treatment monitoring capabilities and remote data capture, aligning with the patient monitoring category.
|
$260.70M |
$14.52
-1.43%
|
|
Inozyme's lead program INZ-701 targets ENPP1 Deficiency, a rare genetic disorder, placing the company squarely in Biotech - Rare Diseases.
|
$256.96M |
$4.00
|
|
Apraglutide targets a rare-disease indication (SBS-IF) and is part of Ironwood's strategic pivot into Rare Diseases.
|
$256.48M |
$1.58
-15.24%
|
|
Puma Biotechnology directly develops oncology therapies and commercializes NERLYNX, a cancer drug, aligning with Biotech - Oncology.
|
$254.15M |
$5.12
-2.29%
|
|
Directly produces and develops oral small molecule therapeutics (NLRP3 inhibitors) for autoimmune, inflammatory, and neuroinflammatory diseases.
|
$253.33M |
$3.56
-7.77%
|
|
Recurring-revenue consumables model around device ecosystems (tips, serums, solutions) aligns with consumables for medical devices.
|
$251.99M |
$1.76
-0.56%
|
|
Solésence provides contract development and manufacturing services for beauty and personal care brands (CDMO).
|
$249.57M |
$3.56
-1.11%
|
|
Sagimet Biosciences designs and develops FASN inhibitors (denifanstat, TVB-3567) for metabolic diseases and oncology, aligning with Biotech - Oncology.
|
$247.10M |
$7.67
-10.96%
|
|
Narsoplimab and OMS1029/zaltenibart are monoclonal antibody therapeutics.
|
$245.50M |
$4.19
-8.71%
|
|
Zura Bio's lead and pipeline assets are immunology-focused antibodies (e.g., tibulizumab targeting IL-17A and BAFF), placing the company squarely in Immunology Therapeutics.
|
$243.17M |
$3.94
+0.13%
|
|
Symvess is an implantable vascular conduit (prosthetic/implantable device) derived from bioengineered tissue, directly aligning with Prosthetics & Implants.
|
$241.99M |
$1.56
-4.29%
|
|
Directly develops autologous mRNA CAR-T cell therapy (Descartes-08) for autoimmune diseases.
|
$241.89M |
$9.32
-8.09%
|
|
Lifecore operates as a pure-play CDMO focused on sterile injectable manufacturing (contract manufacturing for pharma/biotech).
|
$240.66M |
$6.50
-2.40%
|
|
Lanifibranor is Inventiva's lead asset, an orally administered small molecule therapeutic in Phase 3 for MASH, representing the core product focus.
|
$238.77M |
$4.55
-6.19%
|
|
OraSure directly manufactures and sells diagnostic equipment and self-testing devices (OraQuick self-tests, CT/NG molecular test platform) used for infectious disease diagnostics.
|
$238.61M |
$3.20
+0.31%
|
|
Silence's core business is RNAi therapeutics, anchored by its mRNAi GOLD GalNAc siRNA platform and wholly-owned programs.
|
$235.84M |
$5.00
-7.41%
|
|
Enanta is actively developing antiviral small-molecule therapeutics (RSV programs and related assets), aligning with the 'Antiviral Small-Molecule Therapeutics' theme.
|
$235.57M |
$11.02
-4.26%
|
|
Vor Biopharma's core focus is oncology therapies developed via engineered cell/gene therapies for blood cancers.
|
$234.05M |
$37.46
+1.57%
|
|
Company is a clinical-stage oncology biotech developing MasterKey targeted cancer therapies (BDTX-1535, BDTX-4933).
|
$232.57M |
$4.09
-6.41%
|
|
Core drug delivery platform enabling intracellular delivery of therapeutics across multiple programs.
|
$231.14M |
$6.09
-10.44%
|
|
Company is a clinical-stage biotechnology firm focused on oncology therapies (MICVO ADC).
|
$229.21M |
$3.70
-3.39%
|
|
Lonigutamab is a monoclonal antibody therapeutic developed by ACELYRIN for Thyroid Eye Disease.
|
$228.61M |
$2.27
|
|
Nanox ARC/X are medical imaging systems, a core product line in the company's business.
|
$228.24M |
$3.90
-5.80%
|
|
Company focuses its proprietary siRNA therapies on rare diseases and orphan conditions (PV is rare) with high unmet needs.
|
$226.72M |
$1.60
|
|
Foghorn Therapeutics is a clinical-stage biotech focused on oncology therapies targeting the chromatin regulatory (epigenetic) system, aligning with Biotech - Oncology.
|
$226.31M |
$4.06
-8.76%
|
|
ESK-001 and A-005 are oral small-molecule TYK2 inhibitors, a core direct product category.
|
$224.15M |
$4.29
+4.25%
|
|
Atebimetinib is an oral small-molecule therapeutic being developed for oncology.
|
$220.59M |
$6.13
-2.23%
|
|
Directly develops AAV-based gene therapies for cardiovascular and neurodegenerative genetic diseases (LX2006/LX2020).
|
$219.76M |
$6.62
-1.05%
|
|
Nyxoah directly manufactures and provides the Genio system implant, a surgical medical device used to deliver neurostimulation therapy for obstructive sleep apnea.
|
$219.40M |
$6.38
-6.86%
|
|
Patient monitoring and telemetry features associated with respiratory devices.
|
$219.40M |
$8.16
-4.00%
|
|
Utilizes a proprietary drug delivery platform to target therapeutics to brain tumors, bypassing the blood-brain barrier.
|
$219.38M |
$11.53
-1.11%
|
|
Quanterix manufactures ultra-sensitive diagnostic instruments and platforms (HD-1, SR-X, SP-X, HD-X).
|
$219.00M |
$5.64
-6.00%
|
|
Direct product platform: a polymer-based micro-sphere drug delivery platform enabling local, extended-release therapeutics (Diffusphere) used in EP-104IAR and EP-104GI.
|
$216.23M |
$6.07
-1.78%
|
|
Core product line is the PURE EP Platform for intracardiac electrophysiology, fitting under cardiology devices.
|
$215.15M |
N/A
|
|
Codexis is pivoting to RNAi therapeutics manufacturing using the ECO Synthesis platform, aiming to become a direct supplier of siRNA materials.
|
$214.57M |
$2.59
-7.50%
|
|
Directly manufactures and sells surgical equipment in the form of a robotic TKA system and related components.
|
$214.13M |
$6.00
|
|
Directly developing oncology therapies via gene-edited cell therapies (CAR-T), i.e., Biotech - Oncology.
|
$213.91M |
$2.30
+5.50%
|
|
GNFT's core business is oral small-molecule therapeutics (elafibranor in PBC; additional drug candidates GNS561 and VS-01) across liver diseases.
|
$212.11M |
$4.25
-2.29%
|
|
CVRx directly manufactures and sells Barostim, an implantable neuromodulation device for heart failure, fitting Neuromodulation Devices.
|
$210.41M |
$7.88
+0.51%
|
|
Lead product Foralumab is a fully human monoclonal antibody, making Monoclonal Antibody Therapeutics a core directly produced asset.
|
$210.30M |
$2.04
-5.56%
|
|
Electromed designs and manufactures medical device components used in its SmartVest HFCWO therapy system.
|
$210.24M |
$25.07
+1.79%
|
|
Immunology Therapeutics: Aclaris develops therapies for immune-inflammatory diseases (e.g., atopic dermatitis, psoriasis) and autoimmune conditions.
|
$207.90M |
$1.90
-1.04%
|
|
CRGX directly developed autologous CAR T-cell therapies (firi-cel) and related cell-therapy programs (CRG-23), which are core, direct products.
|
$206.13M |
$4.47
|
|
Utah Medical Products directly manufactures surgical devices such as the Filshie Clip System used in obstetrics/gynecology procedures.
|
$205.35M |
$63.22
+0.51%
|
|
ProQR's core Axiomer platform is a gene therapy–style RNA editing technology with clinical programs AX-0810 and AX-2402.
|
$203.04M |
$2.41
-3.98%
|
|
ASMB's core business is the discovery and development of small-molecule antiviral therapies for HSV genital herpes, HDV, and HBV, representing a distinct antiviral small-molecule therapeutics category.
|
$202.47M |
$26.51
-1.67%
|
|
TARA-2.00 is a cell therapy platform (OK-432) developed by Protara; a core product category is cell therapy.
|
$201.40M |
$5.22
-8.42%
|
|
Rocky Brands provides Contract Manufacturing services, including third-party production and Navy orders.
|
$198.32M |
$26.58
-4.87%
|
|
The company emphasizes compatibility with prefilled syringes, a core feature of its delivery platform.
|
$197.94M |
$4.29
+0.23%
|
|
Core product: OmniAb's antibody discovery platform (Biological Intelligence) enabling generation of human antibodies via engineered transgenic animals and AI/ML.
|
$197.57M |
$1.61
-11.26%
|
|
Exagen directly provides autoimmune diagnostic laboratory testing and advisory services via its AVISE CTD platform and related biomarker assays.
|
$197.13M |
$10.95
-0.64%
|
|
Company directly develops and commercializes monoclonal antibody therapeutics, including PEMGARDA, and a pipeline candidate (VYD2311).
|
$195.54M |
$1.63
+9.40%
|
|
Heron Therapeutics' main products are oncology supportive-care drugs (CINVANTI, SUSTOL) and NK1 receptor antagonist APONVIE for post-operative nausea/vomiting, aligning with Biotech - Oncology.
|
$195.28M |
$1.28
-2.29%
|
|
LOQTORZI is a monoclonal antibody PD-1 inhibitor and the lead product, representing direct monoclonal antibody therapeutics.
|
$193.61M |
$1.67
-9.73%
|
|
InfuSystem is expanding into wound care through partnerships and capabilities, including wound care devices and services.
|
$193.60M |
$9.23
-3.95%
|
|
BioAge's lead programs (BGE-102 and APJ agonists) are oral small-molecule therapeutics for obesity/metabolic disease, directly describing their product category.
|
$191.80M |
$5.35
-2.01%
|
|
Genelux develops oncolytic viral immunotherapies for cancer, anchored by Olvi-Vec, fitting Biotech - Oncology.
|
$191.32M |
$5.07
-7.82%
|
|
CDMO services are a core outsourced drug development function, aligning with Contract Research Organizations.
|
$191.30M |
$11.04
-8.08%
|
|
NexoBrid and EscharEx are enzymatic debridement products used in wound care, aligning with the Wound Care Devices category.
|
$190.99M |
$18.17
+1.34%
|
|
GPS and SLS009 are oncology-focused therapeutics developed by SELLAS Life Sciences.
|
$190.58M |
$1.91
-1.04%
|
|
CRBP's core strategy focuses on oncology therapies, including targeted antibody–drug conjugates and immunotherapy approaches.
|
$190.16M |
$15.54
-2.08%
|
|
Home Health Monitoring Devices represent the at-home health monitoring product line stemming from HealthBeacon.
|
$188.94M |
$13.80
-2.82%
|
|
Protalix develops recombinant protein therapies for rare diseases (Elelyso and Elfabrio) and has a pipeline focused on rare renal indications.
|
$188.17M |
$2.36
+5.36%
|
|
Core business is building off-the-shelf cell therapies (CAR T and CAR NK) derived from iPSCs for multiple indications.
|
$187.42M |
$1.64
+0.31%
|
|
Accuray's CyberKnife and TomoTherapy/Radixact platforms incorporate integrated medical imaging for treatment planning and guidance.
|
$184.39M |
$1.72
-3.91%
|
|
NeuroStar Advanced Therapy System is a neuromodulation medical device, representing the core product Neuronetics sells.
|
$183.64M |
$2.79
-5.10%
|
|
Lead programs are orally bioavailable small-molecule degraders (MonoDACs/BiDACs), aligning with Oral Small Molecule Therapeutics.
|
$171.84M |
$2.42
-6.20%
|
|
Eledon's direct product focus is tegoprubart, an immunology therapeutic (anti-CD40L antibody) in transplantation, placing the company squarely in Immunology Therapeutics.
|
$171.26M |
$2.86
+0.35%
|
Showing page 6 of 11 (1072 total stocks)
Loading industry metrics...
Loading comparison data...
